51029-20-0

Basic information

• Product Name: Benzonitrile, 4-(3-methyl-1-triazenyl)-
• CAS NO: 51029-20-0
• Molecular Formula: C8H8N4
• Molecular Weight: 160.178
• Mol File: 51029-20-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-(3-methyl-1-triazenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-(3-methyl-1-triazenyl)-(51029-20-0)
• EPA Substance Registry System: Benzonitrile, 4-(3-methyl-1-triazenyl)-(51029-20-0)

Safety Data

• Hazardous Substances Data: 51029-20-0(Hazardous Substances Data)

Upstream product

• 73779-16-5 C₉H₁₀N₄O 
• 873-74-5 4-Aminobenzonitrile 
• 1407791-47-2 C₂₂H₃₁N₅O₅ 
• 1407791-41-6 3-[4-nitrophenoxycarbonyl]-1-(4-cyanophenyl)-3-methyltriazene 
• 1407791-34-7 C₁₄H₁₅N₅O₅ 
• 64-17-5 ethanol 
• 122779-50-4 C₁₀H₇F₃N₄O 
• 42548-79-8 3-Acetyl-1-(p-cyanphenyl)-3-methyltriazen 

Downstream Products

• 540-67-0 ethyl methyl ether 
• 873-74-5 4-Aminobenzonitrile 
• 1407791-34-7 C₁₄H₁₅N₅O₅ 
• 1407791-47-2 C₂₂H₃₁N₅O₅ 
• 1147743-30-3 3-(2-(acetylamino)acetyl)-1-(4-cyanophenyl)-3-methyltriazene 
• 1147743-48-3 3-(2-(benzoylamino)propanoyl)-1-(4-cyanophenyl)-3-methyltriazene 
• 1147743-33-6 3-(2-(acetylamino)-3-phenylpropanoyl)-1-(4-cyanophenyl)-3-methyltriazene 
• 1147743-41-6 1-(4-cyanophenyl)-3-methyl-3-(2-(propanoylamino)propanoyl)triazene 
• 1147743-37-0 3-(2-(acetylamino)-3-methylbutanoyl)-1-(4-cyanophenyl)-3-methyltriazene 
• 1147743-27-8 3-(2-(acetylamino)propanoyl)-1-(4-cyanophenyl)-3-methyltriazene 

Relevant articles and documents

Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?

Glioblastoma (GBM) is the most common and aggressive type of brain tumor in adults. The triazene Temozolomide (TMZ), an alkylating drug, is the classical chemotherapeutic agent for gliomas, but has been disappointing against the highly invasive and resist

The selective cytotoxicity of new triazene compounds to human melanoma cells

Metastatic melanoma still remains one the most difficult cancers to overcome. The aim of our research was the design of anti-tumour triazene compounds 3 for application to a melanoma-specific therapy. The strategy exploits the unique enzyme pathway of melanin biosynthesis for conversion of non-toxic prodrugs into toxic drugs in the melanoma cell. The compounds 3 were designed by coupling two active moieties, the alkylating triazenes and different tyrosinase substrates. All compounds 3 revealed to be chemically stable in isotonic phosphate buffer (PBS) at physiologic pH (t??≥?48?h), and most of them showed to be slowly hydrolysed in human plasma (1.5?≤?t? (h)?≤?161). Compounds 3c–n revealed to be excellent tyrosinase substrates (0.74?≤?t? (min)?≤?6) with the best tyrosinase substrate 3l releasing MMT 45?s after tyrosinase activation. Structure-activity relationship studies allowed the identification of the better structural features for enzyme affinity. Furthermore, the derivatives 3l and 3m showed cell selectivity with significant cytotoxic effects (IC50 values of 46–65?μM) against melanoma cell lines with tyrosinase overexpression MNT-1 and B16F10.

Development of triazene prodrugs for ADEPT strategy: New insights into drug delivery system based on carboxypeptidase G2 activation

Six novel urea triazene prodrugs have been synthesized to apply in antibody-directed enzyme prodrug therapy (ADEPT). The chemical and plasmatic stability of l-glutamate triazene prodrugs were evaluated and the chemical reactivity was mainly attributed to